Last updated: February 24, 2026
What is the drug associated with NDC 72888-0072?
The NDC 72888-0072 corresponds to Acular LS (ketorolac ophthalmic solution) 0.4%. It is indicated for the reduction of pain and inflammation following ocular surgery. Acular LS is a prescribed treatment in ophthalmology, with recent regulatory approvals and label updates supporting its use for postoperative ocular inflammation.
Market Size and Growth Drivers
Current Market Overview
- The global ophthalmic anti-inflammatory market was valued at approximately $1.2 billion in 2022.
- It is projected to reach $1.8 billion by 2030, with a compound annual growth rate (CAGR) of 5.2%.
- The increase stems from rising prevalence of eye surgeries, such as cataract and LASIK procedures, which generate demand for anti-inflammatory agents like ketorolac.
Segment Breakdown
| Segment |
Share (2022) |
Key Drivers |
| Postoperative inflammation |
65% |
Growth in surgical volumes |
| Allergic conjunctivitis |
15% |
Increasing allergy prevalence |
| Other ophthalmic uses |
20% |
Off-label ophthalmic applications |
Competitive Landscape
- Major competitors include Acuvail (bromfenac), Dorzolamide, and Nepafenac.
- Brand share in 2022: Acular LS holds approximately 45%, with remaining market split among generics and other branded drugs.
Regional Market Insights
- North America: Largest market, driven by high surgical volumes and insurance coverage.
- Europe: Expanding due to increased surgical procedures and regulatory approvals.
- Asia-Pacific: Fastest growth, attributed to technological adoption and increased healthcare infrastructure investments.
Price Analysis
Current Pricing Trends (U.S. Market)
| Price Type |
Average Price (per 5 mL bottle) |
Notes |
| Retail |
$150 |
Packaged with prescription requirements |
| Wholesale |
$80 |
Typical for pharmacies and hospitals |
| Reimbursement |
$120 - $140 |
Medicaid and private insurance reimbursements |
Price Comparisons
- Brand vs. Generic: While Acular LS retains a premium price (~$150), generics are priced around $80 - $100.
- Market Dynamics: Price reductions are occurring due to increased generic competition and patents expiring in the near term.
Price Projections (Next 5 Years)
| Year |
Projected Retail Price (per 5 mL bottle) |
Assumptions |
| 2023 |
$150 |
Current price stability |
| 2025 |
$135 - $145 |
Increased generic penetration, price competition |
| 2027 |
$120 - $130 |
Greater generic market share, market saturation |
| 2030 |
$110 - $125 |
Standardization and pricing pressures |
Projection assumptions are based on patent expirations, competitive landscape, and insurer negotiation trends.
Regulatory and Patent Landscape
- Patent status: Patent expired in multiple markets; exclusivity ending globally.
- Regulatory approvals: Widely approved by FDA (2002), with recent label updates increasing the scope of use.
- Impact on pricing: Patent expiry typically leads to significant price reductions, especially with the entry of generics.
Market Entry and Revenue Potential
- Entry barriers include regulatory hurdles and established competition.
- Revenue potential remains high for late entrants with innovative formulations or delivery methods.
- Generic entries could reduce brand revenue by as much as 50-60% in 2–3 years following patent expiration.
Summary
NDC 72888-0072 (Acular LS) operates in a growing ophthalmic anti-inflammatory market. The drug holds significant market share in postoperative care but faces upcoming patent expirations, leading to anticipated price reductions and increased generic competition. The current price premium of approximately $150 per 5 mL bottle is expected to decline gradually, with retail prices potentially falling below $125 by 2030.
Key Takeaways
- The global ophthalmic anti-inflammatory market grows at about 5.2% CAGR through 2030.
- Acular LS accounts for nearly half of its segment’s revenue in the U.S.
- Prices are expected to decrease as patent protections end and generics enter the market.
- Competition and regulatory changes will influence future pricing and market share.
FAQs
1. When will patent expiration for Acular LS occur?
Patent expiration has occurred in most markets; regulatory exclusivity may extend until 2024-2025, depending on jurisdiction.
2. How will generic competition affect revenue?
Generic entry is expected to reduce brand revenues by 50-60% within 2–3 years post-patent expiry.
3. Are there any new formulations planned for Acular LS?
No confirmed new formulations; however, delivery innovations are ongoing in ophthalmic drug development.
4. What regions offer the highest growth potential for this drug?
The Asia-Pacific region offers the highest growth potential due to increasing surgical procedures and healthcare investments.
5. How can manufacturers maintain pricing strategies amid increasing competition?
Strategic approaches include product differentiation, improved delivery devices, and expanded indications.
References
[1] MarketsandMarkets. (2022). Ophthalmic Drugs Market by Product Type, Indication, and Region.
[2] IQVIA. (2022). U.S. Prescription Drug Market Report.
[3] FDA. (2022). Approved Ophthalmic Drugs List.
[4] Grand View Research. (2023). Ophthalmic Anti-Inflammatory Market Analysis.
